Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model

Cytotherapy

Volumn 15, Issue 10, 2013, Pages 1297-1306

  Geller, Melissa A ^a   Knorr, David A ^a,b   Hermanson, David A ^a,b   Pribyl, Lee ^a   Bendzick, Laura ^a,b   Mccullar, Valarie ^a   Miller, Jeffrey S ^a   Kaufman, Dan S ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Bioluminescent imaging; Immunotherapy; Natural killer (NK) cells; Ovarian cancer

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; ENGRAFTMENT; FEMALE; FLOW CYTOMETRY; LYMPHOCYTE MIGRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

BIOLUMINESCENT IMAGING; IMMUNOTHERAPY; NATURAL KILLER (NK) CELLS; OVARIAN CANCER;

ADENOCARCINOMA; ANIMALS; ANTIGENS, DIFFERENTIATION; CANCER VACCINES; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; OVARIAN NEOPLASMS; PERITONEAL CAVITY; RECURRENCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883230121     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.05.022     Document Type: Article

References (30)

1. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002, 5:20-28.
2. Carlsten M., Bjorkstrom N.K., Norell H., Bryceson Y., van Hall T., Baumann B.C., et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 2007, 67:1317-1325.
3. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
4. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., et al. Aphase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
5. Tian X., Hexum M.K., Penchev V.R., Taylor R.J., Schultz L.D., Kaufman D.S. Bioluminescent imaging demonstrates that transplanted human embryonic stem cell-derived CD34+ cells preferentially develop into endothelial cells. Stem Cells 2009, 27:2675-2685.
6. Denman C.J., Senyukov V.V., Somanchi S.S., Phatarpekar P.V., Kopp L.M., Johnson J.L., et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 2012, 7:e30264.
7. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. JIntern Med 2009, 266:154-181.
8. Ljunggren H.-G., Malmberg K.-J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007, 7:329-339.
9. Skak K., Frederiksen K.S., Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 2008, 123:575-583.
10. Berg M., Lundqvist A., McCoy P., Samsel L., Fan Y., Tawab A., et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11:341-355.
11. Huenecke S., Zimmermann S.Y., Kloess S., Esser R., Brinkmann A., Tramsen L., et al. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. JImmunother 2010, 33:200-210.
12. Judson P.L., Geller M.A., Bliss R.L., Boente M.P., Downs L.S., Argenta P.A., et al. Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol 2003, 91:389-394.
13. Huntington N.D., Legrand N., Alves N.L., Jaron B., Weijer K., Plet A., et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. JExp Med 2009, 206:25-34.
14. Geller M.A., Miller J.S. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 2011, 3:1445-1459.
15. Gruenbacher G., Gander H., Nussbaumer O., Nussbaumer W., Rahm A., Thurnher M. IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells. Cancer Res 2010, 70:9611-9620.
16. Yamamura S., Matsumura N., Mandai M., Huang Z., Oura T., Baba T., et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer 2012, 130:20-28.
17. Liao S., Liu J., Lin P., Shi T., Jain R.K., Xu L. TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res 2011, 17:1415-1424.
18. Wilson E.B., El-Jawhari J.J., Neilson A.L., Hall G.D., Melcher A.A., Meade J.L., et al. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS ONE 2011, 6:6.
19. Cheng M., Ma J., Chen Y., Zhang J., Zhao W., Wei H., et al. Establishment, characterization and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line. Cell Transplant 2011, 7:7.
20. Sun J.C., Lopez-Verges S., Kim C.C., Derisi J.L., Lanier L.L. NK cells and immune "memory". J Immunol 2011, 186:1891-1897.
21. Cooper M.A., Yokoyama W.M. Memory-like responses of natural killer cells. Immunol Rev 2010, 235:297-305.
22. Cooper M.A., Elliott J.M., Keyel P.A., Yang L., Carrero J.A., Yokoyama W.M. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A 2009, 106:1915-1919.
23. Lopez-Vergès S., Milush J.M., Pandey S., York V.A., Arakawa-Hoyt J., Pircher H., et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010, 116:3865-3874.
24. Waldmann T.A., Lugli E., Roederer M., Perera L.P., Smedley J.V., Macallister R.P., et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011, 117:4787-4795.
25. Francois G., Cédric M., Francois M., Laurence Z. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006, 214:229-238.
26. Barao I., Hanash A.M., Hallett W., Welniak L.A., Sun K., Redelman D., et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2006, 103:5460-5465.
27. Bjo N.K. CD56 negative NK cells: origin, function, and rolein chronic viral disease. Trends Immunol 2010, 31:401-406.
28. Ndhlovu L.C., Lopez-Vergès S., Barbour J.D., Jones R.B., Jha A.R., Long B.R., et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012, 119:3734-3743.
29. McCullar V., Oostendorp R., Panoskaltsis-Mortari A., Yun G., Lutz C.T., Wagner J.E., et al. Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. Exp Hematol 2008, 36:598-608.
30. Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P., et al. Aplacebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. NEngl J Med 2010, 362:387-401.